Clinical Trials Logo

Hepatitis C Genotype 1 clinical trials

View clinical trials related to Hepatitis C Genotype 1.

Filter by:
  • None
  • Page 1

NCT ID: NCT02716428 Completed - Chronic Hepatitis C Clinical Trials

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

Start date: May 2016
Phase: Phase 2
Study type: Interventional

Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.

NCT ID: NCT01471574 Completed - Clinical trials for Hepatitis C, Genotype 1

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Start date: December 2011
Phase: Phase 3
Study type: Interventional

The purpose of this open label study is to evaluate the safety and efficacy of daclatasvir plus pegylated interferon-alfa 2a and ribavirin in untreated hepatitis C virus in patients coinfected with HIV

NCT ID: NCT01464827 Completed - Chronic Hepatitis C Clinical Trials

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Start date: October 2011
Phase: Phase 2
Study type: Interventional

This is a study of combination direct-acting antiviral agents (DAA) with or without ribavirin (RBV) in patients with chronic Hepatitis C Virus (HCV).

NCT ID: NCT01221298 Completed - Hepatitis C Clinical Trials

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-072 and ribavirin (RBV) in treatment-naïve participants with genotype 1 chronic hepatitis C virus (HCV) infection.

NCT ID: NCT01074008 Completed - Hepatitis C Clinical Trials

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

Champion2
Start date: March 2010
Phase: Phase 2
Study type: Interventional

This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072 in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.